Dr. Diane Ginsburg has been accepted into the Leadership Texas 2021 class by Leadership Women, Inc. She will represent The University of Texas at Austin during Leadership Texas sessions through November 2021.
Neuroscience graduate student Cherish Taylor took home the top prize in the Graduate School’s Three Minute Thesis competition. Taylor is a graduate student in the lab of Somshuvra Mukhopadhyay, M.B.B.S., Ph.D. in the College of Pharmacy’s Division of Pharmacology and Toxicology.
Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.
Associate Professor Somshuvra Mukhopadhyay, M.B.B.S., Ph.D. wins the 2020 Co-op Research Excellence Award for Best Paper. The awards are presented each year by the Office of the Vice President for Research and the University Co-operative Society.
P4 students in each of the college’s five experiential regions chose a local Preceptor of the Year for 2020 based on their rotations during the 2019-20 academic year. Past recipients of the Wm. Arlyn Kloesel Preceptor of the Year award declared Kristin Janzen, Pharm.D. this year’s winner.
Associate Dean for Research and Graduate Studies John H. Richburg, Ph.D. received notice from the National Institutes of Health (NIH) awarding him a research grant for a five-year term. The NIH’s grant award for Dr. Richburg’s research totals $2,694,316.
The University of Texas at Austin has named Dr. Samuel Poloyac the next dean of the College of Pharmacy. He will begin serving October 15. Poloyac is a professor of pharmaceutical sciences and the associate dean for graduate and postdoctoral programs at the University of Pittsburgh School of Pharmacy. He will succeed M. Lynn Crismon, who served as dean for 13 years of distinguished leadership in the college.
Researchers in the Division of Molecular Pharmaceutics and Drug Delivery, led by Robert O. (Bill) Williams III, plan to use their novel thin-film-freezing technology to deliver remdesivir through dry powder inhalation, potentially making COVID-19 antiviral treatment more potent, easier to administer, and more broadly available.